Clinical outcomes of COVID-19 in patients with liver cirrhosis - a propensity-matched analysis from a multicentric Brazilian cohort.

Background: Cirrhosis has been pointed out as a clinical entity that leads to worse clinical prognosis in COVID-19 patients. However, this concept is controversial in the literature. We aimed to evaluate clinical outcomes by comparing patients with cirrhosis to those without cirrhosis in a Brazilian cohort.

TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate.

Background: Germline heterozygous pathogenic variants (PVs) in TP53 cause Li-Fraumeni syndrome (LFS), a condition associated with increased risk of multiple tumor types. As the associated cancer risks were refined over time, clinical criteria also evolved to optimize diagnostic yield. The implementation of multi-gene panel germline testing in different clinical settings has led to the identification of TP53 PV carriers outside the classic LFS-associated cancer phenotypes, leading to a broader cancer phenotypic redefinition and to the renaming of the condition as "heritable TP53-related cancer syndrome" (hTP53rc).

Characterization and Biomedical Applications of Electrospun PHBV Scaffolds Derived from Organic Residues.

This study explores the characterization and application of poly(3-hydroxybutyrate--3-hydroxyvalerate) (PHBV) synthesized from organic residues, specifically milk and molasses. Six PHBV samples with varying 3-hydroxyvalerate (3HV) content (7%, 15%, and 32%) were analyzed to assess how 3HV composition influences their properties. Comprehensive characterization techniques, including NMR, FTIR, XRD, DSC, TGA, and tensile-stress test, were used to evaluate the molecular structure, thermal properties, crystalline structure, and mechanical behavior.

Microbubble-Protected Oncolytic Virotherapy Targeted by Sonoporation Induces Tumor Necrosis and T-Lymphocyte Infiltration in Humanized Mice Bearing Triple-Negative Breast Cancer.

Oncolytic virotherapy has shown great promise in mediating targeted tumor destruction through tumor-selective replication and induction of anti-tumor immunity; however, obstacles remain for virus candidates to reach the clinic. These include avoiding neutralizing antibodies, preventing stimulation of the adaptive immune response during intravenous administration, and inducing sufficient apoptosis and immune activation so that the body's defense can work to eradicate systemic disease. We have developed a co-formulation of oncolytic viruses (OVs) with Imagent lipid-encapsulated, perfluorocarbon microbubbles (MBs) to protect the OVs from the innate and adaptive immune system.

Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium.

Aim: To evaluate the efficacy of 25Gy/5# prophylactic pelvic nodal irradiation for regional control during stereotactic radiotherapy (SBRT) for high risk prostate cancer.

Methods: The multinational XXXX consortium database of patients treated with curative-intent prostate SBRT for high risk prostate cancer was queried for prophylactic radiotherapy 25Gy/5# to the pelvic lymph nodes. Details of Phoenix-defined biochemical failure, and location of recurrence (local, regional, or distant) were extracted.